XML 62 R46.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Acquisitions (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | ---
Sep. 30, 2018 USD ($) program | Apr. 30, 2017 USD ($) | Jul. 31, 2016 USD ($) shares | Sep. 30, 2017 USD ($) | Mar. 31, 2017 | Dec. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Dec. 31, 2016 USD ($)
Acquisitions |  |  |  |  |  |  |  |
Number of gene therapy programs for neurologic LSDs developed | program | 10 |  |  |  |  |  |  |
Charges to research expense for stock issued in asset acquisition |  |  |  |  |  | $ 0 | $ 0 | $ 4,607
Loss on impairment of assets |  |  |  |  |  | 0 | 465,427 | 0
Changes in fair value of contingent consideration payable |  |  |  |  |  | 3,300 | (234,322) | 6,760
Contingent consideration payable |  |  |  |  |  | 19,700 | 25,400 |
Contingent consideration payable |  |  |  |  |  | 0 | 8,400 |
Contingent consideration payable, non-current portion |  |  |  |  |  | 19,700 | 17,000 |
Milestone Payment\ | Callidus |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  | 9,000 |  |
Fixed assets |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Loss on impairment of assets |  |  |  |  |  |  | 1,700 |
MiaMed Inc |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Asset acquisition, total consideration, stock and cash |  |  | $ 6,500 |  |  |  |  |
Asset acquisition, cash consideration paid |  |  | 1,800 |  |  |  |  |
Asset acquisition, potential aggregate deal value |  |  | $ 89,500 |  |  |  |  |
Charges to research expense for stock issued in asset acquisition |  |  |  |  |  |  |  | $ 6,500
MiaMed Inc | Amicus | Common Stock |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Consideration paid in common stock | shares |  |  | 825,603 |  |  |  |  |
Scioderm |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Enrollment rate |  |  |  |  | 100.00% |  |  |
Milestone payment |  | $ 10,000 |  |  |  |  |  |
Loss on impairment of assets |  |  |  |  |  |  | $ 463,700 |
Changes in fair value of contingent consideration payable |  |  |  | $ 254,700 |  |  |  |
Selling , general and administrative costs due to wind-down |  |  |  | 400 |  |  |  |
Research and development expenses due to wind-down |  |  |  | 8,100 |  |  |  |
Income tax expense (benefit) due to wind-down |  |  |  | $ (164,700) |  |  |  |
Callidus |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Contingent consideration payable |  |  |  |  |  | 28,700 |  |
Contingent consideration payable |  |  |  |  |  | 9,000 |  |
Contingent consideration payable, non-current portion |  |  |  |  |  | 19,700 |  |
Callidus | Changes in fair value of contingent consideration payable |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Changes in fair value of contingent consideration payable |  |  |  |  |  | $ 3,300 |  |
Clinical, Regulatory and Commercial milestones | MiaMed Inc | Maximum |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Contingent consideration payable upon achievement of milestones |  |  | $ 83,000 |  |  |  |  |
Celenex |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Research and development expense | $ 100,000 |  |  |  |  |  |  |
Contingent consideration based on the achievement of certain milestones | 15,000 |  |  |  |  |  |  |
Contingent consideration based on the achievement of regulatory milestones | 262,000 |  |  |  |  |  |  |
Maximum payment under contingent consideration over the next 4 years | 75,000 |  |  |  |  |  |  |
Celenex | Nationwide Children's Hospital |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Contingent consideration based on the achievement of certain milestones | $ 7,800 |  |  |  |  |  |  |

X
- Definition Asset Acquisition, Consideration Transferred + References No definition available. + Details
Name: | fold_AssetAcquisitionConsiderationTransferred
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Includes payments for achievement of certain clinical, regulatory and commercial milestones. + References No definition available. + Details
Name: | fold_BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of contingent consideration payable in a business asset acquisition upon achievement of certain clinical, regulatory and commercial milestones. + References No definition available. + Details
Name: | fold_BusinessAssetAcquisitionContingentConsiderationMilestones
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of shares of equity interests issued or issuable to acquire entity. + References No definition available. + Details
Name: | fold_BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix: | fold_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The company enrollment percent achieved during the year. + References No definition available. + Details
Name: | fold_BusinessCombinationOfEnrollmentRate
Namespace Prefix: | fold_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of milestone payment. + References No definition available. + Details
Name: | fold_ContingentConsiderationMilestonePayment
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Income Tax Expense (Benefit) Due To Wind-Down + References No definition available. + Details
Name: | fold_IncomeTaxExpenseBenefitDueToWindDown
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number Of Gene Therapy Programs For Neurologic LSDs Developed + References No definition available. + Details
Name: | fold_NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped
Namespace Prefix: | fold_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of a controlling interest in another entity or an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment). + References No definition available. + Details
Name: | fold_PaymentsToAcquireBusinessAssets
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of research and development expenses due to wind-down of operations. + References No definition available. + Details
Name: | fold_ResearchAndDevelopmentExpensesDueToWindDown
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of research expense charged to statement of operations for stock issued in assets acquisition transaction. + References No definition available. + Details
Name: | fold_ResearchExpenseForStockIssuanceInAssetAcquisition
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Revenue Recognition, Milestone Method, Contingent On Development + References No definition available. + Details
Name: | fold_RevenueRecognitionMilestoneMethodContingentOnDevelopment
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue Recognition, Milestone Method, Contingent On Submission And Approval Milestones + References No definition available. + Details
Name: | fold_RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue Recognition, Milestone Method, Maximum Expected Payment Over Next Four Years + References No definition available. + Details
Name: | fold_RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of selling, general and administrative costs due to wind-down of operations. + References No definition available. + Details
Name: | fold_SellingGeneralAndAdministrativeCostsDueToWindDown
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228 + Details
Name: | us-gaap_AssetImpairmentCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 4 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph b -URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph b -URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130533-203044 + Details
Name: | us-gaap_ContractWithCustomerAssetNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=fold_MilestonePaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=fold_CallidusBiopharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PropertyPlantAndEquipmentByTypeAxis=fold_FixedAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=fold_MiamedIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=fold_ChangesInFairValueOfContingentConsiderationPayableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | fold_AssetAcquisitionAxis=fold_CelenexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=fold_NationwideChildrensHospitalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |